Teva Pharmaceutical Industries Ltd (TEVA) stock
TEVANYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 3, 2026Score 7/30127% above fair value
$42.62+0.05 (+0.12%)
Close on Nov 17, 2026Market cap $49.66BP/E 71.0Yield –
Teva Pharmaceutical Industries net income
Net income is the profit left for shareholders after every expense, interest and tax.
Teva Pharmaceutical Industries's net income for the twelve months ending Jun 30, 2026 was $706.00M. For fiscal 2025 it was $1.41B. Over ten years it grew -1.2% a year on average. The highest annual figure on record is $3.33B in fiscal 2010.
Annual net income
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $1.41B | – |
| FY2024 | Dec 31, 2024 | -$1.64B | – |
| FY2023 | Dec 31, 2023 | -$559.00M | – |
| FY2022 | Dec 31, 2022 | -$2.45B | -686.6% |
| FY2021 | Dec 31, 2021 | $417.00M | – |
| FY2020 | Dec 31, 2020 | -$3.99B | – |
| FY2019 | Dec 31, 2019 | -$999.00M | – |
| FY2018 | Dec 31, 2018 | -$2.15B | – |
| FY2017 | Dec 31, 2017 | -$16.27B | -5043.8% |
| FY2016 | Dec 31, 2016 | $329.00M | -79.3% |
| FY2015 | Dec 31, 2015 | $1.59B | -48.0% |
| FY2014 | Dec 31, 2014 | $3.06B | +140.7% |
| FY2013 | Dec 31, 2013 | $1.27B | -35.4% |
| FY2012 | Dec 31, 2012 | $1.96B | -28.9% |
| FY2011 | Dec 31, 2011 | $2.76B | -17.2% |
| FY2010 | Dec 31, 2010 | $3.33B | +66.5% |
| FY2009 | Dec 31, 2009 | $2.00B | +228.4% |
| FY2008 | Dec 31, 2008 | $609.00M | -68.2% |
| FY2007 | Dec 31, 2007 | $1.91B | – |
Quarterly net income
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | -$576.00M | -304.3% |
| Q1 FY2026 | Mar 31, 2026 | $369.00M | +72.4% |
| Q4 FY2025 | Dec 31, 2025 | $480.00M | – |
| Q3 FY2025 | Sep 30, 2025 | $433.00M | – |
| Q2 FY2025 | Jun 30, 2025 | $282.00M | – |
| Q1 FY2025 | Mar 31, 2025 | $214.00M | – |
| Q4 FY2024 | Dec 31, 2024 | -$217.00M | -146.9% |
| Q3 FY2024 | Sep 30, 2024 | -$437.00M | -733.3% |
| Q2 FY2024 | Jun 30, 2024 | -$846.00M | – |
| Q1 FY2024 | Mar 31, 2024 | -$139.00M | – |
| Q4 FY2023 | Dec 31, 2023 | $463.00M | – |
| Q3 FY2023 | Sep 30, 2023 | $69.00M | +13.1% |
| Q2 FY2023 | Jun 30, 2023 | -$872.00M | – |
| Q1 FY2023 | Mar 31, 2023 | -$220.00M | – |
| Q4 FY2022 | Dec 31, 2022 | -$1.30B | – |
| Q3 FY2022 | Sep 30, 2022 | $61.00M | -79.1% |
| Q2 FY2022 | Jun 30, 2022 | -$251.00M | -221.3% |
| Q1 FY2022 | Mar 31, 2022 | -$955.00M | -1340.3% |
| Q4 FY2021 | Dec 31, 2021 | -$159.00M | -206.0% |
| Q3 FY2021 | Sep 30, 2021 | $292.00M | – |
| Q2 FY2021 | Jun 30, 2021 | $207.00M | +47.9% |
| Q1 FY2021 | Mar 31, 2021 | $77.00M | +11.6% |
| Q4 FY2020 | Dec 31, 2020 | $150.00M | +36.4% |
| Q3 FY2020 | Sep 30, 2020 | -$4.35B | – |
| Q2 FY2020 | Jun 30, 2020 | $140.00M | – |
| Q1 FY2020 | Mar 31, 2020 | $69.00M | – |
| Q4 FY2019 | Dec 31, 2019 | $110.00M | – |
| Q3 FY2019 | Sep 30, 2019 | -$314.00M | – |
| Q2 FY2019 | Jun 30, 2019 | -$689.00M | – |
| Q1 FY2019 | Mar 31, 2019 | -$105.00M | -109.4% |
| Q4 FY2018 | Dec 31, 2018 | -$2.89B | – |
| Q3 FY2018 | Sep 30, 2018 | -$208.00M | -135.0% |
| Q2 FY2018 | Jun 30, 2018 | -$176.00M | – |
| Q1 FY2018 | Mar 31, 2018 | $1.12B | +73.6% |
| Q4 FY2017 | Dec 31, 2017 | -$11.54B | – |
| Q3 FY2017 | Sep 30, 2017 | $595.00M | +44.4% |
| Q2 FY2017 | Jun 30, 2017 | -$5.97B | – |
| Q1 FY2017 | Mar 31, 2017 | $645.00M | – |
| Q4 FY2016 | Dec 31, 2016 | -$973.00M | – |
| Q3 FY2016 | Sep 30, 2016 | $412.00M | – |
See a number that looks wrong?